Hypermethylation of tumor suppressors and immune response genes and the fact that DNMTs are overexpressed in cancer have made them therapeutic targets (e.g., DNMT1) (Fig. 2; Mizuno et al. 2001; Esteller 2008; Zhang et al. 2020; Pappalardi et al. 2021). The gene discussed is DNMT1; the disease is cancer.